Drug intelligence / Profile preview

SDF-1(S4V)

Development stage: Preclinical
Modality: Recombinant Proteins and Enzymes, Peptides
Administration: Intramyocardial, Local Delivery

Overview

SDF-1(S4V) is an engineered, protease-resistant variant of the chemokine stromal cell-derived factor-1 alpha (SDF-1α), also known as CXCL12. It is designed to resist cleavage by proteases such as dipeptidylpeptidase-4 (DPP-4)/CD26 and matrix metalloproteinase-2 (MMP-2), which are often upregulated in injured tissues and can inactivate native SDF-1α. This enhanced stability allows for sustained biological activity. SDF-1(S4V) functions as an agonist of the CXCR4 receptor, attracting stem and progenitor cells and promoting processes like angiogenesis and neovascularization. It has been investigated for its potential in cardioprotection following myocardial infarction and for improving blood flow in peripheral artery disease.

Targets

CXCR4 (C-X-C motif chemokine receptor 4)

Beyond the preview

Go deeper on SDF-1(S4V).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SDF-1(S4V).

Explore the full profile